Skip to main content

Jordi Bove Badell

I am a Principal Investigator in the Neurodegenerative Diseases Group at the Vall d'Hebron Research Institute (VHIR) and my lines of research focus on the study of the mechanisms of neuronal death in Parkinson's disease and the development of preventive and therapeutic strategies for this disease and related diseases.

Institutions of which they are part

Main researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Jordi Bove Badell

Institutions of which they are part

Main researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

I am a Principal Investigator in the Neurodegenerative Diseases Group at the Vall d'Hebron Research Institute (VHIR) and my lines of research focus on the study of the mechanisms of neuronal death in Parkinson's disease and the development of preventive and therapeutic strategies for this disease and related diseases.

I received a Pharmacy degree from the University of Barcelona in 1998. In 2003, I got a PhD in Pharmacy (Neurobiology) with cum laude distinction from the same university at the Experimental Neurology Laboratory, Neurological Service of Hospital Clínic de Barcelona-IDIBAPS (Dr. C. Marin/Prof. E. Tolosa). My doctoral thesis shed light on the mechanism of levodopa-induced motor fluctuations in Parkinson's disease. I later joined the laboratory of Dr. Serge Przedborski at Columbia University (New York, USA) as a post-doctoral researcher (2003-2005), working on animal modeling and the role of alpha-synuclein in Parkinson's disease. In 2006 I co-founded the Neurodegenerative Diseases Research Group at Vall d’Hebron Research Institute (VHIR) in the Vall d’Hebron Hospital Campus (Barcelona) with its leader Dr. Miquel Vila. In 2011, I obtained a position as a Miguel Servet Investigator (Instituto de Salud Carlos III, Spain) as a Researcher in the National System of Health, and since then I am one of the principal investigators of the group. The research that I am leading is aimed to elucidate the mechanism of neuron cell death and to determine new therapeutic targets to develop neuroprotective strategies for Parkinson’s disease and other neurodegenerative diseases. I am also interested in establishing presymptomatic biomarkers of Parkinson´s disease. I am currently focused on the role of the adaptive immune system in Parkinson’s disease. Our latest published study suggests that a cytotoxic attack induced by CD8 T lymphocytes initiates the disease.

Research lines

Neuronal dysfunction and immune response in Parkinson's disease

IP: Jordi Bove Badell

Projects

Malalties neurodegeneratives

IP: Miquel Vila Bover
Collaborators: Jorge Hernández Vara, Joan Compte Barrón, Marta Martínez Vicente, Jordi Bove Badell, Eddie Pradas Gracia, Maria Camprodon Gomez, Camille Guillard Sirieix, Marina Lorente Picón, Laura Castillo Ribelles, Oriol de Fabregues-Boixar Nebot, Javier Hoyo Pérez, Ariadna Laguna Tuset, Thais Cuadros Arasa, Jordi Riera Heredia, David Ramos Vicente, Marta Montpeyó Garcia-Moreno, Helena Xicoy Cortada, Alba Nicolau Vera, Marta González Sepúlveda, Joana Margalida Cladera Sastre, Annabelle Parent, Daniela Samaniego Toro
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00784
Duration: 01/01/2022 - 31/12/2024

Pendent

IP: Jordi Bove Badell
Collaborators: David Ramos Vicente, Miriam Izquierdo Sans, Laia Perez Lasarte
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 64800
Reference: FJC2021-047862-I
Duration: 01/01/2023 - 31/12/2024

Ministerio de Ciencia

Characterization of the CD8 T cell response in Parkinson’s disease for the development of preventive and therapeutic strategies that halt the progression of the disease: SARS-Cov-2-induced long term-hyposmia as a possible prodromal stage

IP: Jordi Bove Badell
Collaborators: Miquel Vila Bover, Alejandro Ferré Masó, Oriol de Fabregues-Boixar Nebot, Carles Lorenzo Bosquet, Thais Cuadros Arasa, Antonio Palasi Franco, David Ramos Vicente, Mariona Marchena Herrera
Funding agency: Instituto de Salud Carlos III
Funding: 165770
Reference: PI21/01358
Duration: 01/01/2022 - 31/12/2024

Estudio de la respuesta inmune adaptativa inducida por epítopos derivados de alfa-sinucleína en pacientes con enfermedad de Parkinson: desarrollo de estrategias neuroprotectoras.

IP: Jordi Bove Badell
Collaborators: Oriol de Fabregues-Boixar Nebot
Funding agency: Instituto de Salud Carlos III
Funding: 141570
Reference: PI18/01894
Duration: 01/01/2019 - 31/12/2022

Related news

Dr. Miquel Vila, head of the Neurodegenerative Diseases research group at VHIR, is the co-chair of the local organising committee. And Dr. Ariadna Laguna, principal investigator of the same group, is a scientific ambassador.

Researchers describe the molecular mechanisms by which the GBA gene, the main genetic risk factor, associates with the accumulation of α-synuclein in neurons.

It is the project “New Nanotechnological Therapy for Parkinson’s disease: Nose to Brain Delivery of GBA-Polymer Nanoconjugates (nanoGBAtoBrain)”.

Related professionals

Valeria Rizzuto

Valeria Rizzuto

Predoctoral researcher
Childhood Cancer and Blood Disorders
Read more
Emanuela Greco

Emanuela Greco

Predoctoral researcher
Read more
Jose Cabral Jamba

Jose Cabral Jamba

Administrative
IT / Information Systems
Digital Transformation and Quality Area
Read more
Sebastián  Sandoval  Moreno

Sebastián Sandoval Moreno

Predoctoral researcher
Rheumatology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.